2021-05-10 07:35:59 GMT2021-05-10 15:35:59(Beijing Time) Xinhua English
HONG KONG, May 10 (Xinhua) A Hong Kong-led global study showed that a hepatitis C virus drug simeprevir can strongly suppress the replication of SARS-CoV-2, the virus that causes COVID-19, according to a press release issued by the Chinese University of Hong Kong (CUHK) on Monday.
Since the beginning of 2020, researchers from the CUHK and the University of Hong Kong have collaborated with over 30 scientists from local and overseas laboratories to search for an effective drug molecule for the treatment of COVID-19.
Using a combination of biochemistry, cell biology and computational chemistry techniques, the team discovered simeprevir can simultaneously target two major viral proteins that are critical to viral replication. Simeprevir is by now the only antiviral drug that can target more than one SARS-CoV-2 protein.
HONG KONG, May 10 (Xinhua): A Hong Kong-led global study showed that a hepatitis C virus drug simeprevir can strongly suppress the replication of SARS-CoV-2, the virus that causes Covid-19, according to a press release issued by the Chinese University of Hong Kong (CUHK) on Monday.
Since the beginning of 2020, researchers from the CUHK and the University of Hong Kong have collaborated with over 30 scientists from local and overseas laboratories to search for an effective drug molecule for the treatment of Covid-19.
Using a combination of biochemistry, cell biology and computational chemistry techniques, the team discovered simeprevir can simultaneously target two major viral proteins that are critical to viral replication. Simeprevir is by now the only antiviral drug that can target more than one SARS-CoV-2 protein.
Gut Microbiota Reflects Disease Severity in COVID-19 Patients
Compared with non-COVID-19 patients, those with COVID-19 showed a substantially changed gut microbiome, whether or not they received medication.
Caption: Image: CC BY 2.0 Go-tea 郭天 Celiac.com 03/15/2021 - COVID-19 is mainly a respiratory illness, but there is mounting evidence to indicate that the gut and gut microbiota may play a role in the disease. A team of researchers recently set out to determine if the gut microbiome is linked to disease severity in patients with COVID-19, and whether variations in microbiome composition might resolve with the passing of the SARS-CoV-2 virus. The research team included Yun Kit Yeoh, Tao Zuo; Grace Chung-Yan Lui; Fen Zhang; Qin Liu; Amy YL Li; Arthur CK Chung; Chun Pan Cheung; Eugene YK Tso; Kitty SC Fung; Veronica Chan; Lowell Ling; Gavin Joynt; David Shu-Cheong Hui; Kai Ming Chow; Susanna So Shan Ng; Timothy Chun-Man Li; Rita WY Ng; Terry CF Yip; Grace Lai-Hung Wong; F